Table 4A.

Randomized control trials of budesonide for induction in microscopic colitis.

Studies	Efficacy	Safety
Miehlke et al. (2002) 12	86.9% clinical remission in budesonide group vs. 13.6% placebo group (p < 0.001)	7.7% discontinued budesonide due to side effects vs. 4.0% placebo group
Baert et al. (2002) 13	8/14 patients in budesonide group had clinical remission vs. 3/14 in placebo (p = 0.05)	No serious adverse events reported in either group
Bonderup et al. (2003) 14	10/10 patients in budesonide group had clinical remission vs. 2/10 in placebo (p < 0.001)	No side effects were reported in either group
Miehlke et al. (2009) 15	86% clinical remission in budesonide group vs. 48% placebo group (p = 0.10)	10% had side effects in budesonide group vs. 14% in placebo group
Miehlke et al. (2014) 16	80% clinical remission in budesonide group vs. 37.8% placebo group (p = 0.0006)	The rate of adverse events did not differ between groups
Miehlke et al. (2018) 17	79% clinical remission in budesonide group vs. 42% placebo group (p = 0.01)	47.4% adverse events in budesonide group vs. 42.1% placebo group